These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 16968831

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.
    Cochrane Database Syst Rev; 2014 Oct 23; 2014(10):CD007744. PubMed ID: 25340915
    [Abstract] [Full Text] [Related]

  • 7. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 27; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 9. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec 27; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
    Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA.
    Basic Clin Pharmacol Toxicol; 2006 Mar 27; 98(3):266-74. PubMed ID: 16611201
    [Abstract] [Full Text] [Related]

  • 12. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep 27; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 27; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [What do we know about the cardiovascular toxicity of the NSAIDs?].
    Sibilia J, Deray G, Montalescot G.
    Presse Med; 2006 Sep 27; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
    [Abstract] [Full Text] [Related]

  • 17. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC, Ashcroft DM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 27; 16(7):762-72. PubMed ID: 17457957
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2007 Jul 27; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.